Jamison Private Wealth Management Inc. Grows Position in Johnson & Johnson (NYSE:JNJ)

Jamison Private Wealth Management Inc. raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 93.7% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 90,537 shares of the company’s stock after acquiring an additional 43,790 shares during the period. Johnson & Johnson makes up approximately 1.9% of Jamison Private Wealth Management Inc.’s holdings, making the stock its 11th biggest position. Jamison Private Wealth Management Inc.’s holdings in Johnson & Johnson were worth $13,093,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in JNJ. IFS Advisors LLC lifted its holdings in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares during the period. Highline Wealth Partners LLC bought a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $31,000. RPg Family Wealth Advisory LLC purchased a new position in shares of Johnson & Johnson in the third quarter worth approximately $35,000. Mowery & Schoenfeld Wealth Management LLC grew its position in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after buying an additional 91 shares during the period. Finally, Activest Wealth Management purchased a new stake in Johnson & Johnson during the third quarter valued at approximately $40,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In related news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Bank of America cut their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Raymond James reduced their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Wells Fargo & Company decreased their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Finally, Stifel Nicolaus dropped their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $170.44.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $150.63 on Wednesday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The stock has a 50 day moving average of $147.81 and a 200 day moving average of $156.12. The firm has a market cap of $362.65 billion, a PE ratio of 22.65, a PEG ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the firm posted $2.29 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.3% compared to the same quarter last year. On average, research analysts expect that Johnson & Johnson will post 10.56 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.29%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.